Published on May 26, 2021
Is Treatment Choice Affected By MRD Testing?
As CLL treatment becomes more personalized, minimal or measurable residual disease (MRD) testing is increasingly important. Follow along as Patient Power co-founder and CLL patient, Andrew Schorr, is joined by his doctor, Tom Kipps, MD, PhD, Professor of Medicine at UC San Diego, to engage in a deep dive discussion on this topic. They will cover the different MRD tests that are available, when a CLL patient should be tested, and how the results are informing treatment choice.
Support for this series has been provided by Adaptive Biotechnologies, Inc. Patient Power maintains complete editorial control and is solely responsible for program content.
Recommended for You: